Healthcare
Cumberland Pharmaceuticals Inc.(CPIX)
Live Price
Offline$5.72
+1.96% today
1Y Change
+137.25%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +17.6%
- EPS Growth
- +58.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cumberland Pharmaceuticals Inc. (CPIX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $5.72 and up 137.3% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +17.6%, EPS growth of +58.7%, a dividend yield of 0.0%. What stands out right now is revenue +17.6%, EPS +58.7%, free cash flow +710.5% with operating margin -17.2% and ROIC -19.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CPIX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.6% vs +7.6% peer median
Operating Margin
Below sector median
-17.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.6% and EPS at +58.7%, with operating margin around -17.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +7.1% | +19.4% | +21.0% |
2026 May 5, 2026 | โ | -4.0% | -0.4% | +23.3% |
2026 Mar 3, 2026 | +92.3% | -19.9% | -31.0% | -29.0% |
Benchmark Edge
CPIX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CPIX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CPIX Max Drawdown
-52.62%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CPIX and SPY.
Company Overview
Cumberland Pharmaceuticals Inc.
NASDAQ
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative prescription products aimed at improving patient care. The company primarily operates in the healthcare sector, offering a portfolio of niche-market prescription products that address significant medical needs. Cumberland's product range includes treatments for hospital acute care settings, gastroenterology, and oncology, catering to specific therapeutic segments. Founded in 1999 and headquartered in Nashville, Tennessee, the company leverages a network of direct salesforce alongside partnerships with other health care providers and distributors to ensure broad product availability across the United States market. Cumberland Pharmaceuticals plays a critical role in the healthcare industry by providing essential medications that enhance treatment outcomes and address unmet medical needs. Its commitment to expanding therapeutic options and improving patient access to specialized treatments underscores its significance in the pharmaceutical market.
- Leadership
- Mr. A. J. Kazimi MBA
- Employees
- 93
- Street Address
- 1600 West End Avenue, Suite 1300
- Mailing
- Nashville, TN, 37203
- Region
- Nashville, TN, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.6
- Price/Book
- 3.1
Growth
- Revenue
- +17.6%
- EPS
- +58.7%
- Free Cash Flow
- +710.5%
Profitability
- Gross Margin
- 82.9%
- Operating Margin
- -17.2%
- Net Margin
- -17.6%
- ROE
- -29.3%
- ROIC
- -19.5%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 0.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.